Will produce dosage forms including tablets and capsules
Ranbaxy Malaysia is to set up a US$35m greenfield manufacturing facility at Kulim Hi Tech Park (KHTP), a wholly owned state agency and industrial park that houses various other leading industries. KHTP is located at Kulim in the state of Kedah, Malaysia.
The Ranbaxy greenfield facility will be built on an area of around 15 acres and employ more than 200 people. This will be the firm’s second manufacturing plant in Malaysia; the other facility in Sungai Petani Kedah was commissioned in 1987.
T. Jeyabalan Thangarajah, Managing Director of Ranbaxy Malaysia, said: ‘Ranbaxy established its foothold in Malaysia three decades back and since then has been offering high quality, affordable generic medicines to the Malaysian healthcare system. The new greenfield facility reinforces our long term commitment.’
As well as serving the local market, the new facility will export products to the ASEAN markets, Middle East, Europe, Sri Lanka, China and ‘other select nations’.
The new facility will manufacture tablets and capsules primarily in the cardiovascular, diabetes, infections and gastrointestinal therapeutic areas.
When the plant is fully operational, Ranbaxy’s total output in Malaysia will be increased from one billion to three billion dosage forms per annum.
Ranbaxy Malaysia is a joint venture company of Indian generics manufacturer Ranbaxy Laboratories, India and Malaysian shareholders. Established in 1982, the firm is now one of the major generic companies in this market.